Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (48)Etcamah approved in the EU for ER+ breast cancer
Preheader (128)Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer
Typography
Arial
Colors
Text Analysis
Body Words151
Subject Words9
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px788 px
X-Spam Score0.0
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeEvening

Etcamah approved in the EU for ER+ breast cancer

Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer
Etcamah approved in the EU for ER+ breast cancer